A Randomized Phase 2 Trial of Bevacizumab with or without Daily Low-Dose Interferon Alfa-2b in Metastatic Malignant Melanoma

Abstract

Vascular endothelial growth factor (VEGF) is a proangiogenic molecule produced by melanoma cells. We hypothesized that administration of bevacizumab (Bev), a monoclonal antibody that neutralizes VEGF, with low-dose interferon alfa-2b (IFN-α2b), an inhibitor of basic fibroblast growth factor (FGF), would lead to the regression of metastatic melanoma… (More)
DOI: 10.1245/s10434-007-9389-5

Topics

6 Figures and Tables

Slides referencing similar topics